Growth hormone (GH) has been used for over 35 years, and its safety and efficacy has been studied extensively. Experimental studies showing the permissive role of GH/insulin-like growth factor 1 (IGF-I) in carcinogenesis have raised concerns regarding the safety of GH replacement in children and adults who have received treatment for cancer and those with intracranial and pituitary tumours. A consensus statement was produced to guide decision-making on GH replacement in children and adult survivors of cancer, in those treated for intracranial and pituitary tumours and in patients with increased cancer risk. With the support of the European Society of Endocrinology, the Growth Hormone Research Society convened a Workshop, where 55 international key opinion leaders representing 10 professional societies were invited to participate. This consensus statement utilized: (1) a critical review paper produced before the Workshop, (2) five plenary talks, (3) evidence-based comments from four breakout groups, and (4) discussions during report-back sessions. Current evidence reviewed from the proceedings from the Workshop does not support an association between GH replacement and primary tumour or cancer recurrence. The effect of GH replacement on secondary neoplasia risk is minor compared to host- and tumour treatment-related factors. There is no evidence for an association between GH replacement and increased mortality from cancer amongst GH-deficient childhood cancer survivors. Patients with pituitary tumour or craniopharyngioma remnants receiving GH replacement do not need to be treated or monitored differently than those not receiving GH. GH replacement might be considered in GH-deficient adult cancer survivors in remission after careful individual risk/benefit analysis. In children with cancer predisposition syndromes, GH treatment is generally contraindicated but may be considered cautiously in select patients.

Individuals surviving cancer and brain tumors may experience growth hormone (GH) deficiency as a result of tumor growth, surgical resection and/or radiotherapy involving the hypothalamic-pituitary region. Given the pro-mitogenic and anti-apoptotic properties of GH and insulin-like growth factor-I, the safety of GH replacement in this population has raised hypothetical safety concerns that have been debated for decades. Data from multicenter studies with extended follow-up have generally not found significant associations between GH replacement and cancer recurrence or mortality from cancer among childhood cancer survivors. Potential associations with secondary neoplasms, especially solid tumors, have been reported, although this risk appears to decline with longer follow-up. Data from survivors of pediatric or adult cancers who are treated with GH during adulthood are scarce, and the risk versus benefit profile of GH replacement of this population remains unclear. Studies pertaining to the safety of GH replacement in individuals treated for nonmalignant brain tumors, including craniopharyngioma and non-functioning pituitary adenoma, have generally been reassuring with regards to the risk of tumor recurrence. The present review offers a summary of the most current medical literature regarding GH treatment of patients who have survived cancer and brain tumors, with the emphasis on areas where active research is required and where consensus on clinical practice is lacking.

SUMÁRIOCrianças nascidas prematuras podem passar por um período de restrição do crescimento logo após o nascimento. A normalização do crescimento tem início nos primeiros meses de vida, podendo ocorrer de forma lenta e progressiva. Muitas vezes essas crianças mantêm-se mais baixas e com menor peso durante toda a infância quando comparadas àquelas nascidas a termo. Em alguns casos, a recuperação completa só ocorre na adolescência. Entretanto, algumas crianças não conseguem recuperar totalmente o ganho de peso e altura, e adultos nascidos prematuros apresentam maior risco de baixa estatura. O comprometimento do crescimento é mais significativo naquelas nascidas prematuras e pequenas para a idade gestacional. Fatores como estatura-alvo, peso ao nascimento, idade gestacional, intercorrências neonatais e escolaridade materna interferem no potencial de crescimento. Especial atenção deve ser dada aos nascidos prematuros durante todo o período de crescimento. Arq Bras Endocrinol Metab. 2011;55(8):534-40 Descritores Crescimento; recém-nascido prematuro; prematuridade; baixo peso ao nascimento; pequeno para a idade gestacional; recuperação do crescimento; curvas de crescimento SUMMARY Children born prematurely might experience a period of growth restriction just after birth. Catch-up growth begins during the first months of life and can be slow and progressive. These children may remain shorter and thinner throughout infancy and childhood compared to children born at term. In some cases, complete catch-up growth occurs only during adolescence. However, some children do not completely recover growth, and adults born prematurely are at increased risk of short stature. Impaired growth is more frequent in those born preterm and small for gestational age. Factors such as target height, birth weight, gestational age, neonatal morbidities and maternal education interfere in growth potential. Special attention should be given to children born preterm during the whole growth period. Arq Bras Endocrinol Metab. 2011;55(8):534-40 Keywords Growth; preterm newborn; premature children; low birthweight; prematurity; small for gestational age; catch-up growth INTRODUÇÃO A tualmente, cerca de 13 milhões de crianças nascem prematuramente em todo o mundo e o número de partos prematuros tem aumentado nos últimos anos (1). A melhoria da assistência obstétrica e o aumento do número de gestações múltiplas, provavelmente em decorrência das técnicas de reprodução assistida, são alguns fatores que contribuem para esse aumento. Dos óbitos que ocorrem no período neonatal, não relacionados a malformações congênitas, 28% resultam de nascimentos prematuros. Estima-se um gasto de mais de 26 bilhões de dólares apenas nos Estados Unidos com problemas relacionados à prematuridade (1).A etiologia da prematuridade é multifatorial e varia de acordo com a idade gestacional (IG). Aproximadamente 14% dos casos podem ser explicados por fatores maternos e 11% por fatores genéticos fetais (2). Infecções maternas predominam como causa de nascimento

No abstract